Oral anticoagulant use for stroke prevention in atrial fibrillation patients with difficult scenarios

Ting Yung Chang, Jo Nan Liao, Tze Fan Chao*, Jennifer Jeanne Vicera, Chin Yu Lin, Ta Chuan Tuan, Yenn Jiang Lin, Shih Lin Chang, Li Wei Lo, Yu Feng Hu, Fa Po Chung, Shih Ann Chen

*此作品的通信作者

研究成果: Review article同行評審

34 引文 斯高帕斯(Scopus)

摘要

Atrial fibrillation (AF) has become the most prevalent arrhythmia and it will increase the risk of ischemic stroke, heart failure, mortality, sudden cardiac death, myocardial infarction, and dementia. Stroke prevention with oral anticoagulant is crucial for management of AF patients. Vitamin K antagonist, which inhibits the clotting factors II, VII, IX and X, has been recommended for stroke prevention for decades. Non-Vitamin K antagonist oral anticoagulants (NOACs), including dabigatran, rivaroxaban, apixaban and edoxaban are at least as effective as warfarin in reducing ischemic stroke with a lower rate of major bleeding. With the increasing prevalence of AF, prescription of the appropriate oral anticoagulants (OACs) according to patient's characteristics becomes a challenge. This review article aims to provide an overview of anticoagulant use in AF patients with difficult scenarios.

原文English
頁(從 - 到)56-62
頁數7
期刊IJC Heart and Vasculature
20
DOIs
出版狀態Published - 9月 2018

指紋

深入研究「Oral anticoagulant use for stroke prevention in atrial fibrillation patients with difficult scenarios」主題。共同形成了獨特的指紋。

引用此